 Home > Active Ingredient News > Blood System > J Clin Oncol: Bonatumumab non-response and high disease burden suggest that B-ALL patients with CD19-CAR treatment have a poor prognosis

J Clin Oncol: Bonatumumab non-response and high disease burden suggest that B-ALL patients with CD19-CAR treatment have a poor prognosis

 Last Update: 2021-12-01
 Source: Internet
 Author: User

Tags

leopard disease

3 5 dimethylphenol

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CD19 targeting chimeric antigen receptor T cells (CD19-CAR) and Bonatumumab can effectively induce remission of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), but they are also related to CD19 antigen regulation

This is a multicenter, retrospective study that analyzed the prognosis of children and adolescents with relapsed or refractory ALL who received CD19-CAR treatment from 2012 to 2019

child

Cumulative recurrence rate of patients in each subgroup

Of the 420 patients (median age 12.

The complete remission rate (20/31, 64.

After D19-CAR treatment, compared with Bonatumumab responders or patients who did not receive Bonatumumab treatment, those who did not respond to Bonatumumab treatment had the worst 6-month EFS and RFS.

It is understood that this is by far the largest study of CD19-CAR children, the study results show that Boehner spit monoclonal antibody treatment had no response and high disease burden and B-ALL patients with poor treatment after CD19-CAR EFS and RFS Independently related

Bonatumumab treatment non-response and high disease burden are independently related to poor RFS and EFS after CD19-CAR treatment in B-ALL patients

Original source:

Regina M.

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.